Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA Has Slim Advisory Committee Schedule – A Sign Of Things Not To Come?

Jan 03 2017

• By Derrick Gingery

FDA entrance sign 2016

Related Content

Neurocrine Gets First Drug For Tardive Dyskinesia To FDA

Aug 30 2016

Samsung Bioepis Taps Infliximab As Its US Biosimilar Pioneer

May 24 2016

Keeping Track: US FDA Approves Spinraza And Rubraca, Delays Ocrevus; Plus Submissions Galore

Dec 27 2016

Roche’s Highly Anticipated Ocrelizumab Delayed By Manufacturing Issues

Dec 20 2016

Biosimilar Advisory Committee Reviews: Necessity Or Nuisance?

Jul 20 2016

Pending Biosimilars

Mar 07 2016

User Fee Goal Dates

Mar 07 2016

Biosimilar Template Revisited: Inflectra Approval Binds And Separates From Remicade

Apr 06 2016

Duchenne Group's Presentation Is Milestone For Patient Involvement

May 02 2016

Related Companies

Neurocrine Biosciences, Inc.

Sarepta Therapeutics, Inc.

Roche Holding AG

Samsung Bioepis Co., Ltd.

Johnson & Johnson

Celltrion, Inc.

Additional Topics

United States Advisory Committees Drug Review Regulation FDA BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window